Direct inhibition of protein Ca by site directed thrombin inhibitors: implications in anticoagulant and thrombolytic therapy.
Callas
D D
DD
Department of Pharmacology and Pathology, Loyola University Chicago, Stritch School of Medicine, Maywood, IL 60153, USA.
Fareed
J
J
D000933:Antifibrinolytic Agents / Q000138:chemical synthesis / Q000494:pharmacology*; D000990:Antithrombin III / Q000494:pharmacology; D000991:Antithrombins / Q000138:chemical synthesis / Q000494:pharmacology*; D007611:Aprotinin / Q000494:pharmacology; D001120:Arginine / Q000031:analogs & derivatives; D001665:Binding Sites / Q000187:drug effects; D001896:Boron Compounds / Q000494:pharmacology; D004789:Enzyme Activation / Q000187:drug effects; D005342:Fibrinolysis / Q000187:drug effects; D006493:Heparin / Q000494:pharmacology; D006629:Hirudins / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D009842:Oligopeptides / Q000494:pharmacology; D010446:Peptide Fragments / Q000494:pharmacology; D010875:Pipecolic Acids / Q000494:pharmacology; D011486:Protein C / Q000037:antagonists & inhibitors*; D011994:Recombinant Proteins / Q000494:pharmacology; D013449:Sulfonamides; D013917:Thrombin / Q000378:metabolism
D000933:Antifibrinolytic Agents; D000991:Antithrombins; D001896:Boron Compounds; D006629:Hirudins; D009842:Oligopeptides; D010446:Peptide Fragments; D010875:Pipecolic Acids; D011486:Protein C; D011994:Recombinant Proteins; D013449:Sulfonamides; C066061:acetylphenylalanyl-prolyl-boroarginine; C035202:H-D-Phe-Pro-arginal; C030798:tert-butyloxycarbonyl-phenylalanyl-prolyl-arginal; D000990:Antithrombin III; D006493:Heparin; D007611:Aprotinin; D001120:Arginine; D013917:Thrombin; C031942:argatroban; C074619:bivalirudin; C064289:efegatran